Douglas B. Johnson, M.D.

Assistant Professor

douglas.b.johnson@vanderbilt.edu
Faculty Appointments
Assistant Professor of Medicine
Education
M.S.C.I., Clinical Investigation , Vanderbilt University, Nashville, TennesseeM.D., MEDICINE, University of Alabama, Birmingham, AlabamaB.S., Abilene Christian University, Abilene, Texas
Publications
Johnson DB, Bordeaux JM, Kim JY, Vaupel CA, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy JW, Witte JS, McKee SB, Ko J, Wrangle J, Dabbas B, Tangri S, Lameh J, Hall JM, Markowitz J, Balko JM, Dakappagari NK. Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma. Clin. Cancer Res [print-electronic]. 2018 Jul 7/18/2018; PMID: 30021908, PII: 1078-0432.CCR-18-0309, DOI: 10.1158/1078-0432.CCR-18-0309, ISSN: 1078-0432.

Johnson DB. Toxicities and outcomes: Do steroids matter? [editorial]. Cancer [print-electronic]. 2018 Jul 7/5/2018; PMID: 29975416, DOI: 10.1002/cncr.31627, ISSN: 1097-0142.

Johnson DB, Daniels AB. Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials. JAMA Ophthalmol [print-electronic]. 2018 Jun 6/28/2018; PMID: 29955760, PII: 2686114, DOI: 10.1001/jamaophthalmol.2018.1813, ISSN: 2168-6173.

Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin. Cancer Res [print-electronic]. 2018 Jun 6/13/2018; PMID: 29898988, PII: 1078-0432.CCR-18-1116, DOI: 10.1158/1078-0432.CCR-18-1116, ISSN: 1078-0432.

Davis EJ, Johnson DB, Sosman JA, Chandra S. Melanoma: What do all the mutations mean?. Cancer [print-electronic]. 2018 Apr 4/17/2018; PMID: 29663336, DOI: 10.1002/cncr.31345, ISSN: 1097-0142.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis [letter]. Lancet. 2018 Mar 3/10/2018; 391(10124): 933. PMID: 29536852, PII: S0140-6736(18)30533-6, DOI: 10.1016/S0140-6736(18)30533-6, ISSN: 1474-547X.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol [print-electronic]. 2018 Mar; 19(3): 310-22. PMID: 29449192, PMCID: PMC5840029, PII: S1470-2045(18)30078-0, DOI: 10.1016/S1470-2045(18)30078-0, ISSN: 1474-5488.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature [print-electronic]. 2018 Jan 1/18/2018; 553(7688): 347-50. PMID: 29320474, PMCID: PMC5773412, PII: nature25187, DOI: 10.1038/nature25187, ISSN: 1476-4687.

Wang DY, Johnson DB, Davis EJ. Toxicities Associated With PD-1/PD-L1 Blockade. Cancer J. 2017 Dec; 24(1): 36-40. PMID: 29360726, PMCID: PMC5784852, PII: 00130404-201801000-00007, DOI: 10.1097/PPO.0000000000000296, ISSN: 1540-336X.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018; 7(6): e1438106. PMID: 29872580, PMCID: PMC5975601, PII: 1438106, DOI: 10.1080/2162402X.2018.1438106, ISSN: 2162-4011.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM. BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy. Pigment Cell Melanoma Res [print-electronic]. 2017 Nov 11/24/2017; PMID: 29171936, DOI: 10.1111/pcmr.12674, ISSN: 1755-148X.

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017 Nov 11/21/2017; 5(1): 91. PMID: 29157297, PII: 10.1186/s40425-017-0296-4, DOI: 10.1186/s40425-017-0296-4, ISSN: 2051-1426.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol. 2017 Nov; 24(6): 311-35. PMID: 28777143, PMCID: PMC5638696, DOI: 10.1097/PAP.0000000000000161, ISSN: 1533-4031.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann. Oncol [print-electronic]. 2017 Oct 10/11/2017; PMID: 29045547, PII: 4454832, DOI: 10.1093/annonc/mdx642, ISSN: 1569-8041.

Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J. Clin. Oncol [print-electronic]. 2017 Oct 10/9/2017; JCO2017741025. PMID: 28991513, DOI: 10.1200/JCO.2017.74.1025, ISSN: 1527-7755.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A. MDM2 Antagonists Counteract Drug-Induced DNA Damage. EBioMedicine [print-electronic]. 2017 Sep 9/19/2017; PMID: 29030058, PII: S2352-3964(17)30369-9, DOI: 10.1016/j.ebiom.2017.09.016, ISSN: 2352-3964.

Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin. Cancer Biol [print-electronic]. 2017 Sep 9/14/2017; PMID: 28917578, PII: S1044-579X(17)30121-9, DOI: 10.1016/j.semcancer.2017.09.004, ISSN: 1096-3650.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Adv Anat Pathol. 2017 Sep; 24(5): 235-51. PMID: 28777142, PMCID: PMC5564448, DOI: 10.1097/PAP.0000000000000162, ISSN: 1533-4031.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS. Recurrent tumor cell-intrinsic and -extrinsic alterations during MAPKi-induced melanoma regression and early adaptation. Cancer Discov [print-electronic]. 2017 Sep 9/1/2017; PMID: 28864476, PII: 2159-8290.CD-17-0401, DOI: 10.1158/2159-8290.CD-17-0401, ISSN: 2159-8290.

Zhou AY, Johnson DB. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. Am J Clin Dermatol [print-electronic]. 2017 Aug 8/31/2017; PMID: 28861871, PII: 10.1007/s40257-017-0320-y, DOI: 10.1007/s40257-017-0320-y, ISSN: 1179-1888.

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, Berger AC, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hoefer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N. Engl. J. Med. 2017 Jun 6/8/2017; 376(23): 2211-22. PMID: 28591523, DOI: 10.1056/NEJMoa1613210, ISSN: 1533-4406.

Morales-Betanzos CA, Lee H, Gonzalez-Ericsson PI, Balko JM, Johnson DB, Zimmerman LJ, Liebler DC. Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol. Cell Proteomics [print-electronic]. 2017 May 5/25/2017; PMID: 28546465, PII: RA117.000037, DOI: 10.1074/mcp.RA117.000037, ISSN: 1535-9484.

Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist [print-electronic]. 2017 May 5/5/2017; PMID: 28476944, PII: theoncologist.2016-0450, DOI: 10.1634/theoncologist.2016-0450, ISSN: 1549-490X.

Davis EJ, Johnson DB. Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. Per Med [print-electronic]. 2017 May; 14(3): 189-92. PMID: 28861116, PMCID: PMC5573119, DOI: 10.2217/pme-2017-0014, ISSN: 1741-0541.

Morales-Betanzos CA, Lee H, Gonzalez-Ericsson PI, Balko JM, Johnson DB, Zimmerman LJ, Liebler DC. WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. Mol. Cell Proteomics [print-electronic]. 2017 Apr 4/17/2017; PMID: 28416578, PII: M117.067942, DOI: 10.1074/mcp.M117.067942, ISSN: 1535-9484.

Roussel M, Ferrell PB, Greenplate AR, Lhomme F, Le Gallou S, Diggins KE, Johnson DB, Irish JM. Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. J. Leukoc. Biol [print-electronic]. 2017 Apr 4/11/2017; PMID: 28400539, PII: jlb.5MA1116-457R, DOI: 10.1189/jlb.5MA1116-457R, ISSN: 1938-3673.

Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman J, Johnson DB, Buchbinder EL. Clinical features of acquired resistance to anti-PD-1 therapy in advanced melanoma. Cancer Immunol Res [print-electronic]. 2017 Apr 4/10/2017; PMID: 28396509, PII: 2326-6066.CIR-16-0287, DOI: 10.1158/2326-6066.CIR-16-0287, ISSN: 2326-6074.

Liang WS, Hendricks W, Kiefer J, Schmidt J, Sekar S, Carpten J, Craig DW, Adkins J, Cuyugan L, Manojlovic Z, Halperin RF, Helland A, Nasser S, Legendre C, Hurley LH, Sivaprakasam K, Johnson DB, Crandall H, Busam KJ, Zismann V, Deluca V, Lee J, Sekulic A, Ariyan CE, Sosman J, Trent J. Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma. Genome Res. 2017 Apr; 27(4): 524-32. PMID: 28373299, PII: gr.213348.116, DOI: 10.1101/gr.213348.116, ISSN: 1549-5469.

Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular Toxicities Associated with Cancer Immunotherapies. Curr Cardiol Rep. 2017 Mar; 19(3): 21. PMID: 28220466, PII: 10.1007/s11886-017-0835-0, DOI: 10.1007/s11886-017-0835-0, ISSN: 1534-3170.

Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer [print-electronic]. 2017 Feb 2/27/2017; PMID: 28241095, DOI: 10.1002/cncr.30642, ISSN: 1097-0142.

Jones MS, Jones PC, Stern SL, Elashoff D, Hoon DS, Thompson J, Mozzillo N, Nieweg OE, Noyes D, Hoekstra HJ, Zager JS, Roses DF, Testori A, Coventry BJ, Smithers MB, Andtbacka R, Agnese D, Schultz E, Hsueh EC, Kelley M, Schneebaum S, Jacobs L, Bowles T, Kashani-Sabet M, Johnson D, Faries MB. The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. Ann. Surg. Oncol [print-electronic]. 2017 Feb 2/21/2017; PMID: 28224364, PII: 10.1245/s10434-017-5775-9, DOI: 10.1245/s10434-017-5775-9, ISSN: 1534-4681.

Moslehi JJ, Johnson DB, Sosman JA. Myocarditis with Immune Checkpoint Blockade [letter]. N. Engl. J. Med. 2017 Jan 1/19/2017; 376(3): 292. PMID: 28099832, DOI: 10.1056/NEJMc1615251, ISSN: 1533-4406.

Beckermann KE, Jolly PC, Kim JY, Bordeaux J, Puzanov I, Rathmell WK, Johnson DB. Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma. J Immunother Cancer. 2017; 5: 1. PMID: 28105368, PMCID: PMC5240268, PII: 206, DOI: 10.1186/s40425-016-0206-1, ISSN: 2051-1426.

Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5: 8. PMID: 28239462, PII: 210, DOI: 10.1186/s40425-017-0210-0, ISSN: 2051-1426.

Siska PJ, Johnpulle RAN, Zhou A, Bordeaux J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK, Morgans AK, Balko JM, Johnson DB. Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. Oncoimmunology. 2017; 6(4): e1305535. PMID: 28507813, PMCID: PMC5414873, PII: 1305535, DOI: 10.1080/2162402X.2017.1305535, ISSN: 2162-4011.

Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology. 2017; 6(10): e1344805. PMID: 29123955, PMCID: PMC5665065, PII: 1344805, DOI: 10.1080/2162402X.2017.1344805, ISSN: 2162-4011.

Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precis Oncol [print-electronic]. 2017; 2017: PMID: 29951597, PMCID: PMC6016848, ISSN: 2473-4284.

Johnson D. Is there a role for single-agent MEK inhibition in melanoma?. Clin Adv Hematol Oncol. 2016 Dec; 14(12): 976-8. PMID: 28212360, ISSN: 1543-0790.

Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ. Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J. Immunother [print-electronic]. 2016 Nov 11/14/2016; PMID: 27846054, DOI: 10.1097/CJI.0000000000000148, ISSN: 1537-4513.

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N. Engl. J. Med. 2016 Nov 11/3/2016; 375(18): 1749-55. PMID: 27806233, DOI: 10.1056/NEJMoa1609214, ISSN: 1533-4406.

Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong AN, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol [print-electronic]. 2016 Sep 9/29/2016; PMID: 27687304, PII: mdw443, DOI: 10.1093/annonc/mdw443, ISSN: 1569-8041.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller V, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res [print-electronic]. 2016 Sep 9/26/2016; PMID: 27671167, PII: 2326-6066.CIR-16-0143, DOI: 10.1158/2326-6066.CIR-16-0143, ISSN: 2326-6074.

Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer [print-electronic]. 2016 Aug 8/17/2016; PMID: 27533633, DOI: 10.1002/cncr.30259, ISSN: 1097-0142.

Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer [print-electronic]. 2016 Aug 8/17/2016; PMID: 27533448, DOI: 10.1002/cncr.30258, ISSN: 1097-0142.

Vilgelm AE, Johnson DB, Richmond A. Combinatorial approach to cancer immunotherapy: strength in numbers. J. Leukoc. Biol [print-electronic]. 2016 Aug; 100(2): 275-90. PMID: 27256570, PII: jlb.5RI0116-013RR, DOI: 10.1189/jlb.5RI0116-013RR, ISSN: 1938-3673.

Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 Aug; 14(8): 945-58. PMID: 27496110, PII: 14/8/945, ISSN: 1540-1413.

Beckermann KE, Johnson DB, Sosman JA. PD-1/PD-L1 blockade in renal cell cancer. Expert Rev Clin Immunol [print-electronic]. 2016 Jul 7/28/2016; 1-8. PMID: 27426025, DOI: 10.1080/1744666X.2016.1214575, ISSN: 1744-8409.

Greenplate AR, Johnson DB, Ferrell PB, Irish JM. Systems immune monitoring in cancer therapy. Eur. J. Cancer [print-electronic]. 2016 Jul; 61: 77-84. PMID: 27155446, PMCID: PMC4885747, PII: S0959-8049(16)32047-0, DOI: 10.1016/j.ejca.2016.03.085, ISSN: 1879-0852.

Shreders A, Joseph R, Peng C, Ye F, Zhao S, Puzanov I, Sosman JA, Johnson DB. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. Cancer Immunol Res [print-electronic]. 2016 Jul; 4(7): 569-73. PMID: 27197063, PMCID: PMC4940026, PII: 2326-6066.CIR-15-0281, DOI: 10.1158/2326-6066.CIR-15-0281, ISSN: 2326-6074.

Johnson DB, Pollack MH, Sosman JA. Emerging targeted therapies for melanoma. Expert Opin Emerg Drugs [print-electronic]. 2016 Jun; 21(2): 195-207. PMID: 27148822, DOI: 10.1080/14728214.2016.1184644, ISSN: 1744-7623.

Johnson DB, Lovly CM, Sullivan RJ, Carvajal RD, Sosman JA. Melanoma driver mutations and immune therapy. Oncoimmunology. 2016 May; 5(5): e1051299. PMID: 27467925, PMCID: PMC4910708, PII: 1051299, DOI: 10.1080/2162402X.2015.1051299, ISSN: 2162-4011.

Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko J, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res [print-electronic]. 2016 Apr 4/18/2016; PMID: 27089234, DOI: 10.1111/pcmr.12482, ISSN: 1755-148X.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. SFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature [print-electronic]. 2016 Apr 4/4/2016; PMID: 27042933, PII: nature17392, DOI: 10.1038/nature17392, ISSN: 1476-4687.

Rioth MJ, Thota R, Staggs DB, Johnson DB, Warner JL. Pragmatic Precision Oncology: The Secondary Uses of Clinical Tumor Molecular Profiling. J Am Med Inform Assoc [print-electronic]. 2016 Mar 3/28/2016; PMID: 27026612, PII: ocw002, DOI: 10.1093/jamia/ocw002, ISSN: 1527-974X.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell [print-electronic]. 2016 Mar 3/24/2016; 165(1): 35-44. PMID: 26997480, PMCID: PMC4808437, PII: S0092-8674(16)30215-X, DOI: 10.1016/j.cell.2016.02.065, ISSN: 1097-4172.

Greenplate AR, Johnson DB, Roussel M, Savona MR, Sosman JA, Puzanov I, Ferrell PB, Irish JM. Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy. Cancer Immunol Res [print-electronic]. 2016 Mar 3/10/2016; PMID: 26966176, PII: 2326-6066.CIR-15-0213, DOI: 10.1158/2326-6066.CIR-15-0213, ISSN: 2326-6074.

Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb 2/1/2016; 2(2): 234-40. PMID: 26633184, PII: 2473508, DOI: 10.1001/jamaoncol.2015.4368, ISSN: 2374-2445.

Mudigonda TV, Wyman K, Spigel DR, Dahlman KB, Greco FA, Puzanov I, Kelley MC, Hainsworth JD, Sosman JA, Johnson DB. A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma [letter]. Pigment Cell Melanoma Res [print-electronic]. 2016 Jan; 29(1): 101-3. PMID: 26176864, DOI: 10.1111/pcmr.12394, ISSN: 1755-148X.

Johnpulle RA, Johnson DB, Sosman JA. Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. Curr Oncol Rep. 2016 Jan; 18(1): 6. PMID: 26743513, PII: 10.1007/s11912-015-0485-6, DOI: 10.1007/s11912-015-0485-6, ISSN: 1534-6269.

Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016; 7: 10582. PMID: 26822383, PMCID: PMC4740184, PII: ncomms10582, DOI: 10.1038/ncomms10582, ISSN: 2041-1723.

Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016; 4: 60. PMID: 27777770, PMCID: PMC5067899, PII: 166, DOI: 10.1186/s40425-016-0166-5.

Johnpulle RA, Conry RM, Sosman JA, Puzanov I, Johnson DB. Responses to immune checkpoint inhibitors in nonagenarians. Oncoimmunology. 2016; 5(11): e1234572. PMID: 27999751, PMCID: PMC5139628, PII: 1234572, DOI: 10.1080/2162402X.2016.1234572, ISSN: 2162-4011.

Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer [print-electronic]. 2015 Dec; 51(18): 2792-9. PMID: 26608120, PMCID: PMC4666799, PII: S0959-8049(15)00821-7, DOI: 10.1016/j.ejca.2015.08.022, ISSN: 1879-0852.

Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR, Wallace DE, Dickson MA, Kudchadkar RR, Sosman JA. Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. J. Clin. Oncol [print-electronic]. 2015 Nov 11/20/2015; 33(33): e122-4. PMID: 24778401, PII: JCO.2013.51.1683, DOI: 10.1200/JCO.2013.51.1683, ISSN: 1527-7755.

Johnson DB, Mudigonda TV, Sosman JA. Melanoma and a Headache. Diagnosis: Hypophysitis. JAMA Oncol. 2015 Nov; 1(8): 1167-8. PMID: 26225893, PII: 2398983, DOI: 10.1001/jamaoncol.2015.2537, ISSN: 2374-2445.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, Moriceau G, Hong A, Dahlman KB, Johnson DB, Sosman JA, Ribas A, Lo RS. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 2015 Sep 9/10/2015; 162(6): 1271-85. PMID: 26359985, PMCID: PMC4821508, PII: S0092-8674(15)01040-5, DOI: 10.1016/j.cell.2015.07.061, ISSN: 1097-4172.

Hutchinson KE, Johnson DB, Johnson AS, Sanchez V, Kuba M, Lu P, Chen X, Kelley MC, Wang Q, Zhao Z, Kris M, Berger MF, Sosman JA, Pao W. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015 Sep 9/8/2015; 6(26): 22348-60. PMID: 26084293, PMCID: PMC4673168, PII: 4255, DOI: 10.18632/oncotarget.4255, ISSN: 1949-2553.

Cohen DN, Lawson SK, Shaver AC, Du L, Nguyen HP, He Q, Johnson DB, Lumbang WA, Moody BR, Prescott JL, Chandra PK, Boyd AS, Zwerner JP, Robbins JB, Tyring SK, Rady PL, Chappell JD, Shyr Y, Infante JR, Sosman JA. Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin. Cancer Res [print-electronic]. 2015 Jun 6/1/2015; 21(11): 2624-34. PMID: 25724524, PMCID: PMC4452444, PII: 1078-0432.CCR-14-2667, DOI: 10.1158/1078-0432.CCR-14-2667, ISSN: 1078-0432.

Johnson DB, Sosman JA. Therapeutic Advances and Treatment Options in Metastatic Melanoma. JAMA Oncol. 2015 Jun; 1(3): 380-6. PMID: 26181188, PII: 2276102, DOI: 10.1001/jamaoncol.2015.0565, ISSN: 2374-2445.

Johnson DB, Peng C, Abramson RG, Ye F, Zhao S, Wolchok JD, Sosman JA, Carvajal RD, Ariyan CE. Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. Oncologist [print-electronic]. 2015 Jun; 20(6): 648-52. PMID: 25964307, PMCID: PMC4571784, PII: theoncologist.2014-0468, DOI: 10.1634/theoncologist.2014-0468, ISSN: 1549-490X.

Thota R, Johnson DB, Sosman JA. Trametinib in the treatment of melanoma. Expert Opin Biol Ther [print-electronic]. 2015 May; 15(5): 735-47. PMID: 25812921, DOI: 10.1517/14712598.2015.1026323, ISSN: 1744-7682.

Johnson DB, Friedman DL, Berry E, Decker I, Ye F, Zhao S, Morgans AK, Puzanov I, Sosman JA, Lovly CM. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res [print-electronic]. 2015 May; 3(5): 464-9. PMID: 25649350, PMCID: PMC4420706, PII: 2326-6066.CIR-14-0217, DOI: 10.1158/2326-6066.CIR-14-0217, ISSN: 2326-6074.

Johnson DB, Puzanov I. Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol. 2015 Apr; 16(4): 15. PMID: 25796376, DOI: 10.1007/s11864-015-0330-z, ISSN: 1534-6277.

Ohri N, Duan F, Machtay M, Gorelick JJ, Snyder BS, Alavi A, Siegel BA, Johnson DW, Bradley JD, DeNittis A, Werner-Wasik M. Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235. J. Natl. Cancer Inst [electronic-print]. 2015 Apr; 107(4): PMID: 25688115, PMCID: PMC4402361, PII: djv004, DOI: 10.1093/jnci/djv004, ISSN: 1460-2105.

Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar; 7(2): 97-106. PMID: 25755682, PMCID: PMC4346215, PII: 10.1177_1758834014567469, DOI: 10.1177/1758834014567469, ISSN: 1758-8340.

Johnson DB, Lovly CM, Flavin M, Panageas KS, Ayers GD, Zhao Z, Iams WT, Colgan M, DeNoble S, Terry CR, Berry EG, Iafrate AJ, Sullivan RJ, Carvajal RD, Sosman JA. Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunol Res. 2015 Mar; 3(3): 288-95. PMID: 25736262, PMCID: PMC4351797, PII: 3/3/288, DOI: 10.1158/2326-6066.CIR-14-0207, ISSN: 2326-6074.

Jiang W, Jia P, Hutchinson KE, Johnson DB, Sosman JA, Zhao Z. Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget. 2015 Feb 2/10/2015; 6(4): 2496-508. PMID: 25537510, PMCID: PMC4385866, PII: 2954, DOI: 10.18632/oncotarget.2954, ISSN: 1949-2553.

Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA, Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB, Algazi A, Sosman JA, Ribas A, Lo RS. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell [print-electronic]. 2015 Feb 2/9/2015; 27(2): 240-56. PMID: 25600339, PMCID: PMC4326539, PII: S1535-6108(14)00469-3, DOI: 10.1016/j.ccell.2014.11.018, ISSN: 1878-3686.

Johnson DB, Puzanov I, Kelley MC. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy [print-electronic]. 2015; 7(6): 611-9. PMID: 26098919, PMCID: PMC4519012, DOI: 10.2217/imt.15.35, ISSN: 1750-7448.

Jackson LK, Johnson DB, Sosman JA, Murphy BA, Epstein JB. Oral health in oncology: impact of immunotherapy. Support Care Cancer [print-electronic]. 2015 Jan; 23(1): 1-3. PMID: 25216852, DOI: 10.1007/s00520-014-2434-6, ISSN: 1433-7339.

Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol. 2014 Dec; 15(4): 658-69. PMID: 25096781, PMCID: PMC4216599, DOI: 10.1007/s11864-014-0305-5, ISSN: 1534-6277.

Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J. Clin. Oncol [print-electronic]. 2014 Nov 11/20/2014; 32(33): 3697-704. PMID: 25287827, PMCID: PMC4226803, PII: JCO.2014.57.3535, DOI: 10.1200/JCO.2014.57.3535, ISSN: 1527-7755.

Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin. Cancer Res [print-electronic]. 2014 Aug 8/15/2014; 20(16): 4186-92. PMID: 24895460, PMCID: PMC4134689, PII: 1078-0432.CCR-13-3270, DOI: 10.1158/1078-0432.CCR-13-3270, ISSN: 1078-0432.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.

Johnson DB, Sosman JA. BRAFV600E-mutant melanoma presenting with cardiac involvement. J Natl Compr Canc Netw. 2014 May; 12(5): 611-5. PMID: 24812130, PMCID: PMC4182311, PII: 12/5/611, ISSN: 1540-1413.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W. Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin. Cancer Res [print-electronic]. 2014 May 5/1/2014; 20(9): 2264-75. PMID: 24599935, PMCID: PMC4008689, PII: 1078-0432.CCR-13-1591, DOI: 10.1158/1078-0432.CCR-13-1591, ISSN: 1078-0432.

Stevens PL, Johnson DB, Thompson MA, Keedy VL, Frangoul HA, Snyder KM. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature. Case Rep Oncol Med [print-electronic]. 2014; 2014: 341980. PMID: 25328733, PMCID: PMC4190830, DOI: 10.1155/2014/341980, ISSN: 2090-6706.

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov [print-electronic]. 2014 Jan; 4(1): 80-93. PMID: 24265155, PMCID: PMC3936420, PII: 2159-8290.CD-13-0642, DOI: 10.1158/2159-8290.CD-13-0642, ISSN: 2159-8290.

Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013 Dec; 1(6): 373-7. PMID: 24490176, PMCID: PMC3905602, DOI: 10.1158/2326-6066.CIR-13-0092, ISSN: 2326-6074.

Johnson DB, Sosman JA. Update on the targeted therapy of melanoma. Curr Treat Options Oncol. 2013 Jun; 14(2): 280-92. PMID: 23420410, DOI: 10.1007/s11864-013-0226-8, ISSN: 1534-6277.

Johnson DB, Savani BN. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?. Exp. Hematol [print-electronic]. 2012 Jul; 40(7): 513-7. PMID: 22542577, PII: S0301-472X(12)00138-5, DOI: 10.1016/j.exphem.2012.04.004, ISSN: 1873-2399.